Clinical features, investigations and management of adolescents with polycystic ovary syndrome

Paediatrics and Child Health

Volumn 10, Issue 10, 2005, Pages 602-608

  Orsino, Angela ^a   Van Eyk, Nancy ^a   Hamilton, Jill ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Adolescents; Metabolic syndrome; Polycystic ovary syndrome

Indexed keywords

ANTIANDROGEN; GLUCOSE; MEDROXYPROGESTERONE ACETATE; METFORMIN; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ANOVULATION; BLOOD PRESSURE MEASUREMENT; CANADA; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL FEATURE; DYSLIPIDEMIA; ECHOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERTENSION; INSULIN RESISTANCE; MENSTRUAL IRREGULARITY; METABOLIC SYNDROME X; OBESITY; OVARY POLYCYSTIC DISEASE; REVIEW;

EID: 31644442847     PISSN: 12057088     EISSN: None     Source Type: Journal    
DOI: 10.1093/pch/10.10.602     Document Type: Review

References (44)

1. Iuorno MJ, Nestler JE. Insulin-lowering drugs in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001;28:153-64.
2. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, eds. Polycystic Ovary Syndrome. Boston: Blackwell Scientific, 1992:377-84.
3. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-9.
4. Lobo RA. Priorities in polycystic ovary syndrome. Med J Aust 2001;174:554-5.
5. Goodman E, Daniels SR, Morrison JA, Huang B, Dolan LM. Contrasting prevalence of and demographic disparities in the World Health Organization and National Cholesterol Education Program Adult Treatment Panel III definitions of metabolic syndrome among adolescents. J Pediatr 2004;145:445-51.
6. Hadjiyannakis S. The metabolic syndrome in children and adolescents. Paediatr Child Health 2005;10:41-7.
7. Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004;350:2362-74.
8. Franks S. Adult polycystic ovary syndrome begins in childhood. Best Pract Res Clin Endocrinol Metab 2002;16:263-72.
9. Dunaif A, Thomas A. Current concepts in the polycystic ovary syndrome. Annu Rev Med 2001;52:401-19.
10. Ibanez L, Potau N, de Zegher F. Precocious pubarche, dyslipidemia, and low IGF binding protein-1 in girls: Relation to reduced prenatal growth. Pediatr Res 1999;46:320-2.
11. Arslanian S, Witchel S. Polycystic ovary syndrome in adolescents: Is there an epidemic? Curr Opin Endocrinol Diabetes 2002;9:32-42.
12. Kent SC, Legro RS. Polycystic ovary syndrome in adolescents. Adolesc Med 2002;13:73-88, vi.
13. Dramusic V, Rajan U, Chan P, Ratnam SS, Wong YC. Adolescent polycystic ovary syndrome. Ann N Y Acad Sci 1997;816:194-208.
14. Macut D, Micic D, Cvijovic G, et al. Cardiovascular risk in adolescent and young adult obese females with polycystic ovary syndrome (PCOS). J Pediatr Endocrinol Metab 2001;14(Suppl 5):1353-59, 65.
15. Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Health 2001;29:160-9.
16. Arslanian SA, Lewy VD, Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: Roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metab 2001;86:66-71.
17. Apter D, Butzow T, Laughlin GA, Yen SS. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism. J Clin Endocrinol Metab 1995;80:2966-73.
18. Ibanez L, Valls C, Ferrer A, Marcos MV, Rodriguez-Hierro F, de Zegher F. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab 2001;86:3595-8.
19. Trent ME, Rich M, Austin SB, Gordon CM. Quality of life in adolescent girls with polycystic ovary syndrome. Arch Pediatr Adolesc Med 2002;156:556-60.
20. Tremblay MS, Willms JD. Secular trends in the body mass index of Canadian children. CMAJ 2000;163:1429-33. (Erratum in 2001;164:970)
21. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: A working group report from the National High Blood Pressure Education Program. Pediatrics 1996;98(4 Pt 1):649-58.
22. Dunaif A. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800.
23. Svahn JC, Feldl F, Raiha NC, Koletzko B, Axelsson IE. Fatty acid content of plasma lipid fractions, blood lipids, and apolipoproteins in children fed milk products containing different quantity and quality of fat. J Pediatr Gastroenterol Nutr 2000;31:152-61.
24. Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2003;27(Suppl 2):S14-6.
25. Ibanez L, Virdis R, Potau N, et al. Natural history of premature pubarche: An auxological study. J Clin Endocrinol Metab 1992;74:254-7.
26. Dimartino-Nardi J. Premature adrenarche: Findings in prepubertal African-American and Caribbean-Hispanic girls. Acta Paediatr Suppl 1999;88:67-72.
27. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141-6.
28. Ibanez L, Potau N, Zampolli M, Rique S, Saenger P, Carrascosa A. Hyperinsulinemia and decreased insulin-like growth factor-binding protein-1 are common features in prepubertal and pubertal girls with a history of premature pubarche. J Clin Endocrinol Metab 1997;82:2283-8.
29. Ibanez L, Dimartino-Nardi J, Potau N, Saenger P. Premature adrenarche - normal variant or forerunner of adult disease? Endocr Rev 2000;21:671-96.
30. Lewy VD, Danadian K, Witchel SF, Arslanian S. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J Pediatr 2001;138:38-44.
31. Legro RS. Insulin resistance in polycystic ovary syndrome: Treating a phenotype without a genotype. Mol Cell Endocrinol 1998;145:103-10.
32. Mather KJ, Hunt AE, Steinberg HO, et al. Repeatability characteristics of simple indices of insulin resistance: Implications for research applications. J Clin Endocrinol Metab 2001;86:5457-64.
33. Vuguin P, Saenger P, Dimartino-Nardi J. Fasting glucose insulin ratio: A useful measure of insulin resistance in girls with premature adrenarche. J Clin Endocrinol Metab 2001;86:4618-21.
34. Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:1017-23.
35. Sinha R, Fisch G, Teague B, et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002;346:802-10. (Erratum in 2002;346:1756)
36. Taylor AE. Polycystic ovary syndrome. Endocrinol Metab Clin North Am 1998;27:877-902, ix.
37. Stanhope R, Adams J, Jacobs HS, Brook CG. Ovarian ultrasound assessment in normal children, idiopathic precocious puberty, and during low dose pulsatile gonadotrophin releasing hormone treatment of hypogonadotrophic hypogonadism. Arch Dis Child 1985;60:116-9.
38. Lord JM, Flight IH, Norman RJ. Mettormin in polycystic ovary syndrome: Systematic review and meta-analysis. BMJ 2003;327:951-3.
39. Ihanez L, Valls C, Potau N, Marcos MV, de Zegher F. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious puharche. J Clin Endocrinol Metab 2000;85:3526-30.
40. Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: Amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 2002;87:1555-9.
41. Ibanez L, Ferrer A, Ong K, Amin R, Dunger D, de Zegher F. Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome. J Pediatr 2004;144:23-9.
42. De Leo V, Lanzetta D, D'Antona D, la Marca A, Morgante G. Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:99-102.
43. Ibanez L, Potau N, Marcos MV, de Zegher F. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: Effect of flutamide. J Clin Endocrinol Metab 2000;85:3251-5.
44. Ibanez L, Ong K, Ferrer A, Amin R, Dunger D, de Zegher F. Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. J Clin Endocrinol Metab 2003;88:2600-6.